MERS-CoV-IN-3

MERS-CoV-IN-3 (compound 6d) inhibits purified MERS-CoV 3CLPro with an IC₅₀ of 1.7 µM; it also inhibits purified SARS-CoV 3CLPro with an IC₅₀ of 0.2 µM^[1].
MERS-CoV-IN-3 (serial dilution; 2 days post-infection) inhibits the replication of MERS-CoV in Huh-7 cells, with an EC₅₀ of 0.6 µM, a CC₅₀ of 58.6 µM, and a selectivity index of 97.9; it reduces the infectious MERS-CoV particles produced by infected Huh-7 cells by approximately 97%^[1].
MERS-CoV-IN-3 (0.1-10 μM; 1 day post-infection) reduces the production of MERS-CoV nucleocapsid protein in infected Huh-7 cells in a dose-dependent manner^[1].
MERS-CoV-IN-3 inhibits the replication of human alpha-coronavirus 229E in MRC-5 cells, with an EC₅₀ of 2.0 µM and a selectivity index > 50.0; it inhibits the replication of human beta-coronavirus OC43 in MRC-5 cells, with an EC₅₀ of 17.7 µM and a selectivity index > 5.7; it also inhibits the replication of feline infectious peritonitis alpha-coronavirus in CRFK cells, with an EC₅₀ of 1.1 µM and a selectivity index > 90.9^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.